Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vir Biotechnology

- PMLiVE

US backs proposal to waive IP protection for COVID-19 vaccines

"Monumental decision" could see IP protections for COVID-19 vaccines temporarily removed

- PMLiVE

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

Drug will be evaluted alone and together with other monoclonal antibodies in the expanded BLAZE-4 trial

- PMLiVE

BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021

BioNTech’s CEO Ugur Sahin said increase in manufacturing will allow for this target to be met

- PMLiVE

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Full-year guidance for BioNTech-partnered vaccine increased to $26bn

- PMLiVE

Novavax is close to finalising a COVID-19 vaccine supply deal with the EU

Reuters reported that the company is planning to send doses to Europe before the end of the year

- PMLiVE

Moderna agrees to supply Gavi with 500 million doses for COVAX

Moderna will deliver an initial 34 million doses to COVAX in the fourth quarter of 2021

- PMLiVE

Versiti launches test for vaccine-related blood clot issues

Launch follows reports of very rare blood clots connected to J&J's vaccine

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week

WHO is also due to review vaccines from Sinopharm and Sinovac for possible EUAs

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

- PMLiVE

Single dose of COVID-19 vaccines ‘significantly’ reduces infections

Infections fell by 65% after first dose of AZ/Oxford or Pfizer/BioNTech vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links